Metagenomi Therapeutics, Inc. (MGX)
| Market Cap | 53.80M -22.7% |
| Revenue (ttm) | 25.21M -51.8% |
| Net Income | -87.87M |
| EPS | -2.36 |
| Shares Out | 37.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 194,051 |
| Open | 1.450 |
| Previous Close | 1.460 |
| Day's Range | 1.410 - 1.450 |
| 52-Week Range | 1.230 - 3.950 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 9.25 (+546.85%) |
| Earnings Date | Mar 5, 2026 |
About MGX
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other... [Read more]
Financial Performance
In 2025, Metagenomi Therapeutics's revenue was $25.21 million, a decrease of -51.79% compared to the previous year's $52.30 million. Losses were -$87.87 million, 12.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MGX stock is "Strong Buy." The 12-month stock price target is $9.25, which is an increase of 546.85% from the latest price.
News
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investig...
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to cre...
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 followin...
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative ...
Metagenomi to Present at Jefferies Global Healthcare Conference in London
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative ...
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce
Metagenomi, Inc. (NASDAQ:MGX) on Tuesday shared new dose range finding data from its MGX-001 hemophilia A program.
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions e...
Metagenomi taps Amazon's custom chips to develop gene-editing tools
Biotech firm Metagenomi said it is using artificial intelligence chips from Amazon.com's cloud computing unit to power some of its work in developing gene-editing technologies.
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $ 205.0 million...
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients u...
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders -
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximate ly 19 months with an encouraging safety prof...
Metagenomi to Present at Upcoming Scientific Meetings
EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its propriet...
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system wit...
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
EMERYVILLE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprie...
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing Appro...
Metagenomi Announces New Appointment to its Board of Directors
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprie...
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprie...
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocat...
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up
Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Metagenomi, Inc. ("Metagen...
FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi
NEW YORK--(BUSINESS WIRE)---- $MGX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Metagenomi, Inc. (“Metagenomi” or the “Company”...